Alzheimer’s Disease Assessment Scale–Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies

Cognitive Changes Preceding Clinical Symptom Onset of Mild Cognitive Impairment and Relationship to ApoE Genotype

(2014) Marilyn Albert et al.   Current Alzheimer Research

New applications of disease genetics and pharmacogenetics to drug development

(2014) Allen D Roses et al.   CURRENT OPINION IN PHARMACOLOGY

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Designing drug trials for Alzheimer’s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force

(2013) Bruno Vellas et al.   Alzheimers & Dementia

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

(2013) Chia-Chen Liu et al.   Nature Reviews Neurology

Fluid Biomarkers in Alzheimer Disease

(2013) K. Blennow et al.   Cold Spring Harbor Perspectives in Medicine

The Neuropsychological Profile of Alzheimer Disease

(2013) S. Weintraub et al.   Cold Spring Harbor Perspectives in Medicine

The ADAS-Cog revisited: Novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials

(2012) Nandini Raghavan et al.   Alzheimers & Dementia

Putting the Alzheimer’s cognitive test to the test I: Traditional psychometric methods

(2012) Jeremy Hobart et al.   Alzheimers & Dementia

Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative

(2012) Joshua D. Grill et al.   NEUROBIOLOGY OF AGING

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Treatment With Cholinesterase Inhibitors and Memantine of Patients in the Alzheimer's Disease Neuroimaging Initiative

(2011) Lon S. Schneider   ARCHIVES OF NEUROLOGY

The relative efficiency of time-to-threshold and rate of change in longitudinal data

(2011) M.C. Donohue et al.   Contemporary Clinical Trials

Testing the Right Target and Right Drug at the Right Stage

(2011) R. A. Sperling et al.   Science Translational Medicine

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

APOE-4 Genotype and Neurophysiological Vulnerability to Alzheimer's and Cognitive Aging

(2009) Susan Bookheimer et al.   Annual Review of Clinical Psychology

Biological markers of amyloid β-related mechanisms in Alzheimer's disease

(2009) Harald Hampel et al.   EXPERIMENTAL NEUROLOGY

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

(2009) Pieter Jelle Visser et al.   LANCET NEUROLOGY

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

(2009) Clifford R Jack et al.   LANCET NEUROLOGY

Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization

(2009) R. C. Petersen et al.   NEUROLOGY

Endpoints for trials in Alzheimer's disease: a European task force consensus

(2008) Bruno Vellas et al.   LANCET NEUROLOGY

Safety and efficacy of galantamine in subjects with mild cognitive impairment

(2008) B. Winblad et al.   NEUROLOGY